Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature
Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of hematologic malignancies which typically respond to standard first-line chemoimmunotherapy regimens. Unfortunately, patients with refractory NHL face a poor prognosis and represent an unmet need for improved therapeutics. We present two cases...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2016/2596423 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850172649633742848 |
|---|---|
| author | Wilfred Delacruz Robert Setlik Arash Hassantoufighi Shyam Daya Susannah Cooper Dale Selby Alexander Brown |
| author_facet | Wilfred Delacruz Robert Setlik Arash Hassantoufighi Shyam Daya Susannah Cooper Dale Selby Alexander Brown |
| author_sort | Wilfred Delacruz |
| collection | DOAJ |
| description | Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of hematologic malignancies which typically respond to standard first-line chemoimmunotherapy regimens. Unfortunately, patients with refractory NHL face a poor prognosis and represent an unmet need for improved therapeutics. We present two cases of refractory CD30+ NHL who responded to novel brentuximab vedotin- (BV-) based regimens. The first is a patient with stage IV anaplastic large cell lymphoma (ALCL) with cranial nerve involvement who failed front-line treatment with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (CHOEP) and second line cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose methotrexate (MTX), and cytarabine (hyperCVAD) with intrathecal- (IT-) MTX and IT-cytarabine, but responded when BV was substituted for vincristine (hyperCBAD). The second patient was a man with stage IV diffuse large B-cell lymphoma (DLBCL) with leptomeningeal involvement whose disease progressed during first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and progressed despite salvage therapy with rituximab, dexamethasone, cytarabine, and cisplatin (R-DHAP) in whom addition of BV to topotecan resulted in a significant response. This report describes the first successful salvage treatments of highly aggressive, double refractory CD30+ NHL using two unreported BV-based chemoimmunotherapy regimens. Both regimens appear effective and have manageable toxicities. Further clinical trials assessing novel BV combinations are warranted. |
| format | Article |
| id | doaj-art-ca1d3ece5fed4f13b9354f2a4da8566f |
| institution | OA Journals |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-ca1d3ece5fed4f13b9354f2a4da8566f2025-08-20T02:20:01ZengWileyCase Reports in Oncological Medicine2090-67062090-67142016-01-01201610.1155/2016/25964232596423Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the LiteratureWilfred Delacruz0Robert Setlik1Arash Hassantoufighi2Shyam Daya3Susannah Cooper4Dale Selby5Alexander Brown6Hematology/Oncology Service, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, TX 78234, USAHematology/Oncology Service, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, TX 78234, USADepartment of Internal Medicine, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, TX 78234, USADepartment of Internal Medicine, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, TX 78234, USAHematology/Oncology Service, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, TX 78234, USADepartment of Pathology, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, TX 78234, USAHematology/Oncology Service, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, TX 78234, USANon-Hodgkin lymphomas (NHLs) are a heterogeneous group of hematologic malignancies which typically respond to standard first-line chemoimmunotherapy regimens. Unfortunately, patients with refractory NHL face a poor prognosis and represent an unmet need for improved therapeutics. We present two cases of refractory CD30+ NHL who responded to novel brentuximab vedotin- (BV-) based regimens. The first is a patient with stage IV anaplastic large cell lymphoma (ALCL) with cranial nerve involvement who failed front-line treatment with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (CHOEP) and second line cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose methotrexate (MTX), and cytarabine (hyperCVAD) with intrathecal- (IT-) MTX and IT-cytarabine, but responded when BV was substituted for vincristine (hyperCBAD). The second patient was a man with stage IV diffuse large B-cell lymphoma (DLBCL) with leptomeningeal involvement whose disease progressed during first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and progressed despite salvage therapy with rituximab, dexamethasone, cytarabine, and cisplatin (R-DHAP) in whom addition of BV to topotecan resulted in a significant response. This report describes the first successful salvage treatments of highly aggressive, double refractory CD30+ NHL using two unreported BV-based chemoimmunotherapy regimens. Both regimens appear effective and have manageable toxicities. Further clinical trials assessing novel BV combinations are warranted.http://dx.doi.org/10.1155/2016/2596423 |
| spellingShingle | Wilfred Delacruz Robert Setlik Arash Hassantoufighi Shyam Daya Susannah Cooper Dale Selby Alexander Brown Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature Case Reports in Oncological Medicine |
| title | Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature |
| title_full | Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature |
| title_fullStr | Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature |
| title_full_unstemmed | Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature |
| title_short | Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature |
| title_sort | novel brentuximab vedotin combination therapies show promising activity in highly refractory cd30 non hodgkin lymphoma a case series and review of the literature |
| url | http://dx.doi.org/10.1155/2016/2596423 |
| work_keys_str_mv | AT wilfreddelacruz novelbrentuximabvedotincombinationtherapiesshowpromisingactivityinhighlyrefractorycd30nonhodgkinlymphomaacaseseriesandreviewoftheliterature AT robertsetlik novelbrentuximabvedotincombinationtherapiesshowpromisingactivityinhighlyrefractorycd30nonhodgkinlymphomaacaseseriesandreviewoftheliterature AT arashhassantoufighi novelbrentuximabvedotincombinationtherapiesshowpromisingactivityinhighlyrefractorycd30nonhodgkinlymphomaacaseseriesandreviewoftheliterature AT shyamdaya novelbrentuximabvedotincombinationtherapiesshowpromisingactivityinhighlyrefractorycd30nonhodgkinlymphomaacaseseriesandreviewoftheliterature AT susannahcooper novelbrentuximabvedotincombinationtherapiesshowpromisingactivityinhighlyrefractorycd30nonhodgkinlymphomaacaseseriesandreviewoftheliterature AT daleselby novelbrentuximabvedotincombinationtherapiesshowpromisingactivityinhighlyrefractorycd30nonhodgkinlymphomaacaseseriesandreviewoftheliterature AT alexanderbrown novelbrentuximabvedotincombinationtherapiesshowpromisingactivityinhighlyrefractorycd30nonhodgkinlymphomaacaseseriesandreviewoftheliterature |